专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明授权

US5980928A Implant for preventing conjunctivitis in cattle 失效
标题翻译：用于预防牛结膜炎的植入物
公开(公告)号：US5980928A
公开(公告)日：1999-11-09
申请号：US902113
申请日：1997-07-29
申请人： Paul B. Terry
发明人： Paul B. Terry
IPC分类号： A61F2/00 , A61F9/00 , A61K9/00
CPC分类号： A61M37/0069 , A61F9/0017 , A61K9/0051 , A61F2250/0067 , A61K9/0024 , Y10S514/914 , Y10S514/954 , Y10S514/955
摘要： A method to reduce the likelihood of conjunctivitis in farm animals, especially cattle, includes the step of injecting an implant containing an antibiotic effective against the microbes associated with conjunctivitis subcutaneously into the animal in close proximity to the eye. Preferably the implant includes a matrix to allow time release of the antibiotic and the implant is placed in the animal near the first part of July. Also preferably the antibiotic is tetracycline.
摘要翻译：一种降低农场动物，特别是牛的结膜炎可能性的方法包括将含有抗生素的植入物注射到与结膜炎相关的微生物皮下注射到紧邻眼睛的动物中的步骤。优选地，植入物包括允许抗生素释放时间的基质，并且在7月的第一部分附近将植入物置于动物体内。还优选地，抗生素是四环素。

22. 发明申请

US20190209467A1 SUSTAINED DRUG DELIVERY IMPLANT 审中-公开
公开(公告)号：US20190209467A1
公开(公告)日：2019-07-11
申请号：US16354692
申请日：2019-03-15
申请人： Allergan, Inc.
发明人： Jane-Guo Shiah , Chetan Pujara
IPC分类号： A61K9/00 , A61K31/498 , A61F9/00 , A61K47/32
CPC分类号： A61K9/0051 , A61F9/0017 , A61F2210/0004 , A61K31/498 , A61K47/32 , Y10S514/912 , Y10S514/913 , Y10S514/953 , Y10S514/954 , Y10S514/956
摘要： Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration.

23. 发明授权

US07354574B2 Treatment of ocular disease 有权
标题翻译：眼病的治疗
公开(公告)号：US07354574B2
公开(公告)日：2008-04-08
申请号：US10289772
申请日：2002-11-07
申请人： Gholam A. Peyman
发明人： Gholam A. Peyman
IPC分类号： A61K31/74 , A61K38/16
CPC分类号： A61K38/13 , A61K9/0048 , A61K9/0051 , Y10S514/954
摘要： A method and article to treat ocular disease with Cyclosporin A alone or with compounds related to Cyclosporin A for intraocular injection or implantation. Treatment does not result in ocular toxicity and encompasses age related macular degeneration, retinitis pigmentosa, and retinopathy such as diabetic retinopathy.
摘要翻译：单独使用环孢菌素A或与环孢菌素A相关的化合物治疗眼部疾病的方法和制品，用于眼内注射或植入。治疗不会导致眼睛毒性并且包括年龄相关性黄斑变性，色素性视网膜炎和视网膜病变，例如糖尿病性视网膜病变。

24. 发明授权

US07087249B2 Treatment of mucosal membranes 有权
公开(公告)号：US07087249B2
公开(公告)日：2006-08-08
申请号：US10131509
申请日：2002-04-23
申请人： Robert Edward Burrell , Antony George Naylor , Peter Howard Moxham
发明人： Robert Edward Burrell , Antony George Naylor , Peter Howard Moxham
IPC分类号： A61K9/00 , A61K9/02 , A61K9/14 , A61K9/70 , A61K9/72 , A61K31/28 , A61K31/282 , A61K33/24 , A61K33/38 , A61P11/00
CPC分类号： A61K9/0024 , A01N59/16 , A61K9/0019 , A61K9/0075 , A61K9/0078 , A61K9/14 , A61K9/7007 , A61K33/24 , A61K33/38 , A61K33/40 , A61K47/34 , A61K47/38 , A61L15/46 , A61L17/145 , A61L27/30 , A61L29/10 , A61L31/082 , A61L2300/102 , A61L2300/104 , A61L2300/404 , A61L2300/452 , A61L2300/606 , A61L2300/624 , A61L2300/63 , Y10S424/15 , Y10S514/825 , Y10S514/826 , Y10S514/829 , Y10S514/83 , Y10S514/849 , Y10S514/851 , Y10S514/853 , Y10S514/861 , Y10S514/862 , Y10S514/864 , Y10S514/865 , Y10S514/88 , Y10S514/881 , Y10S514/882 , Y10S514/886 , Y10S514/887 , Y10S514/90 , Y10S514/901 , Y10S514/902 , Y10S514/912 , Y10S514/914 , Y10S514/925 , Y10S514/931 , Y10S514/932 , Y10S514/933 , Y10S514/934 , Y10S514/944 , Y10S514/951 , Y10S514/953 , Y10S514/954 , Y10S514/956 , Y10S514/958 , Y10S514/964 , Y10S514/965 , Y10S514/966 , Y10S514/967 , Y10S514/968 , Y10S514/969 , Y10T428/31855 , A61K2300/00 , A01N25/04 , A01N25/10 , A01N25/12
摘要： The invention relates to the use of one or more antimicrobial metals preferably selected from silver, gold, platinum, and palladium but most preferably silver, formed with atomic disorder, and preferably in a nanocrystalline form, for reducing inflammation or infection of the mucosal membrane. The antimicrobial metal may be formulated as, or used in the form of, a nanocrystalline coating of one or more antimicrobial or noble metals, a nanocrystalline powder of one or more antimicrobial or noble metals, or a liquid or solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial or noble metals.

25. 发明申请

US20060083792A1 Therapeutic treatments using the direct application of antimicrobial metal compositions 审中-公开
公开(公告)号：US20060083792A1
公开(公告)日：2006-04-20
申请号：US11284507
申请日：2005-11-22
申请人： Scott Gillis
发明人： Scott Gillis
IPC分类号： A61K33/38
CPC分类号： A61K9/0024 , A01N59/16 , A61K9/0019 , A61K9/0075 , A61K9/0078 , A61K9/14 , A61K9/7007 , A61K33/24 , A61K33/38 , A61K33/40 , A61K47/34 , A61K47/38 , A61L15/46 , A61L17/145 , A61L27/30 , A61L29/10 , A61L31/082 , A61L2300/102 , A61L2300/104 , A61L2300/404 , A61L2300/452 , A61L2300/606 , A61L2300/624 , A61L2300/63 , Y10S424/15 , Y10S514/825 , Y10S514/826 , Y10S514/829 , Y10S514/83 , Y10S514/849 , Y10S514/851 , Y10S514/853 , Y10S514/861 , Y10S514/862 , Y10S514/864 , Y10S514/865 , Y10S514/88 , Y10S514/881 , Y10S514/882 , Y10S514/886 , Y10S514/887 , Y10S514/90 , Y10S514/901 , Y10S514/902 , Y10S514/912 , Y10S514/914 , Y10S514/925 , Y10S514/931 , Y10S514/932 , Y10S514/933 , Y10S514/934 , Y10S514/944 , Y10S514/951 , Y10S514/953 , Y10S514/954 , Y10S514/956 , Y10S514/958 , Y10S514/964 , Y10S514/965 , Y10S514/966 , Y10S514/967 , Y10S514/968 , Y10S514/969 , Y10T428/31855 , A61K2300/00 , A01N25/04 , A01N25/10 , A01N25/12
摘要： Therapeutic treatments using the direct application of selected structures of antimicrobial metals in free-standing powder form, solution form and/or suspension form in therapeutically effective amounts. The selected structures of antimicrobial metals serve as an antimicrobial agent, an anti-inflammatory agent, an immuno modulator agent, an enzyme modulator agent, and/or an anti-tumor agent, for human and/or animal use.

26. 发明申请

US20040157825A1 Quinolone carboxylic acid compositions and related methods of treatment 审中-公开
公开(公告)号：US20040157825A1
公开(公告)日：2004-08-12
申请号：US10769019
申请日：2004-02-02
发明人： Samir Roy , Santosh Kumar Chandrasekaran , Katsumi Imamori , Takemitsu Asaoka , Akihiro Shibata , Masami Takahashi , Lyle M. Bowman
IPC分类号： A61K031/553 , A61K031/554 , A61K031/55
CPC分类号： A61K9/0048 , A61K31/55 , A61K31/551 , A61K31/553 , A61K31/554 , A61K47/32 , A61K47/38 , A61K47/40 , Y02A50/473 , Y02A50/475 , Y02A50/483 , Y10S514/912 , Y10S514/954 , Y10S514/964
摘要： The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.

27. 发明授权

US06723350B2 Lubricious coatings for substrates 有权
标题翻译：底漆润滑涂层
公开(公告)号：US06723350B2
公开(公告)日：2004-04-20
申请号：US10131513
申请日：2002-04-23
申请人： Robert Edward Burrell , Hua Qing Yin , Antony George Naylor , Peter Howard Moxham , Walter Carlton Theodore Cholowski , Leonard Salvin Bowlby , David James Field
发明人： Robert Edward Burrell , Hua Qing Yin , Antony George Naylor , Peter Howard Moxham , Walter Carlton Theodore Cholowski , Leonard Salvin Bowlby , David James Field
IPC分类号： A61K900
CPC分类号： A61K9/0024 , A01N59/16 , A61K9/0019 , A61K9/0075 , A61K9/0078 , A61K9/14 , A61K9/7007 , A61K33/24 , A61K33/38 , A61K33/40 , A61K47/34 , A61K47/38 , A61L15/46 , A61L17/145 , A61L27/30 , A61L29/10 , A61L31/082 , A61L2300/102 , A61L2300/104 , A61L2300/404 , A61L2300/452 , A61L2300/606 , A61L2300/624 , A61L2300/63 , Y10S424/15 , Y10S514/825 , Y10S514/826 , Y10S514/829 , Y10S514/83 , Y10S514/849 , Y10S514/851 , Y10S514/853 , Y10S514/861 , Y10S514/862 , Y10S514/864 , Y10S514/865 , Y10S514/88 , Y10S514/881 , Y10S514/882 , Y10S514/886 , Y10S514/887 , Y10S514/90 , Y10S514/901 , Y10S514/902 , Y10S514/912 , Y10S514/914 , Y10S514/925 , Y10S514/931 , Y10S514/932 , Y10S514/933 , Y10S514/934 , Y10S514/944 , Y10S514/951 , Y10S514/953 , Y10S514/954 , Y10S514/956 , Y10S514/958 , Y10S514/964 , Y10S514/965 , Y10S514/966 , Y10S514/967 , Y10S514/968 , Y10S514/969 , Y10T428/31855 , A61K2300/00 , A01N25/04 , A01N25/10 , A01N25/12
摘要： The invention provides methods and kits to form water swellable gel coatings, preferably lubricious coatings, on substrates, and coated substrates thus formed. The coatings contain one or more antimicrobial metals formed with atomic disorder, together with one or more antimicrobial metals formed with atomic disorder such that the coatings provide an antimicrobial and anti-inflammatory effect when wet. The invention also provides a method to produce metal powders by sputtering a coating onto a moving surface, and then scraping the coating with one or more scrapers to produce the metal powder. The method is particularly useful for producing large amounts of nanocrystalline antimicrobial metal powders formed with atomic disorder, useful in the water swellable gel coatings of this invention.
摘要翻译：本发明提供了在基底上形成水可溶胀凝胶涂层，优选润滑涂层的方法和试剂盒，以及如此形成的涂覆的基底。涂层含有一种或多种由原子紊乱形成的抗微生物金属，以及一种或多种由原子紊乱形成的抗微生物金属，使得涂层在湿润时提供抗微生物和抗炎作用。本发明还提供了通过将涂层溅射到移动表面上然后用一个或多个刮刀刮擦涂层以产生金属粉末来生产金属粉末的方法。该方法特别适用于生产大量由原子紊乱形成的纳米晶体抗微生物金属粉末，可用于本发明的水溶胀性凝胶涂层。

28. 发明申请

US20040037867A1 Methods of producing intraocular lenses 有权
标题翻译：生产人工晶状体的方法
公开(公告)号：US20040037867A1
公开(公告)日：2004-02-26
申请号：US10444268
申请日：2003-05-23
发明人： Kenneth A. Hodd , Keith Alfred Dillingham , Jacqueline de Groot
IPC分类号： A61K009/00 , B29C035/08
CPC分类号： A61L27/14 , A61F2/16 , A61F2/1613 , A61F2210/0085 , A61L27/16 , A61L2430/16 , Y10S514/952 , Y10S514/954 , C08L39/06 , C08L33/26
摘要： Methods of producing an intraocular lens include introducing a solution into a lens forming enclosure, wherein the solution comprises discrete crosslinkable units of a size small enough to provide an optically clear solution while contributing to a high refractive index of at least 1.3, performing crosslinking between the units of the solution, and thereby forming a solid lens in the enclosure, optionally under a forming pressure.
摘要翻译：产生眼内透镜的方法包括将溶液引入透镜形成外壳中，其中所述溶液包含离散的可交联单元，其尺寸足够小以提供光学透明溶液，同时有助于至少1.3的高折射率，在单元的溶液，从而在外壳中形成固体透镜，任选地在成形压力下。

29. 发明授权

US06379692B1 Pharmaceutical composition comprising a suspension for the active ingredient 失效
标题翻译：药物组合物，其包含用于活性成分的悬浮液
公开(公告)号：US06379692B1
公开(公告)日：2002-04-30
申请号：US09145900
申请日：1998-09-02
申请人： Leburu Seshagiri Rao
发明人： Leburu Seshagiri Rao
IPC分类号： A61K916
CPC分类号： A61K31/522 , A61K9/0048 , A61K9/06 , A61K9/1688 , Y10S514/912 , Y10S514/951 , Y10S514/954
摘要： A pharmaceutical formulation may be prepared by a method comprising providing the active ingredient in solution in a pharmacologically-acceptable base and mixing the resulting solution with a pharmacologically-acceptable acid in an amount such that the formulation attains a pH in the range of from about 3.5 to about 8.5 to thereby precipitate out the active ingredients, a viscosity-enhancing agent having been incorporated in the formulation prior to or during the mixing with acid. The formulation is suitable for administration of a pharmacologically active ingredient which is sparingly soluble in water at a pH acceptable for administration, for example to the eye of the patient.
摘要翻译：药物制剂可以通过包括在药理学上可接受的碱中提供溶液中的活性成分并将所得溶液与药理学上可接受的酸混合的方法制备，其量使得制剂达到约3.5的pH 至约8.5，从而沉淀出活性成分，在与酸混合之前或期间将粘度增强剂掺入制剂中。该制剂适用于在可接受施用的pH下，例如向患者的眼睛施用微溶于水的药理学活性成分。

30. 发明授权

US5422116A Liquid ophthalmic sustained release delivery system 失效
标题翻译：液体眼科持续释放递送系统
公开(公告)号：US5422116A
公开(公告)日：1995-06-06
申请号：US198924
申请日：1994-02-18
申请人： Shau-Fong Yen , Kenneth W. Reed
发明人： Shau-Fong Yen , Kenneth W. Reed
IPC分类号： A61K9/08 , A61K9/00 , A61K47/36 , A61K47/00
CPC分类号： A61K9/0048 , A61K47/36 , Y10S514/912 , Y10S514/913 , Y10S514/914 , Y10S514/915 , Y10S514/95 , Y10S514/954 , Y10S514/955 , Y10S514/964
摘要： Disclosed is a sustained release liquid aqueous ophthalmic delivery system and a method of providing a slow and sustained release of ophthalmic treating agents to the eye of a mammal which comprises administering to the eye of a said mammal an effective amount of a homogeneous liquid aqueous ophthalmic pharmaceutical composition, of pH between about 3.0 and about 6.2, which is adminstrable in drop form and which comprises an ophthalmically effective concentration of a said ophthalmic treating agent and about 0.05% to about 10% by weight of the polymer chitosan; said polymer consisting essentially of(A) monomeric .beta.(1.fwdarw.4)-D-glucosamine linked units and of(B) monomeric .beta.(1.fwdarw.4)-D-glucosamine linked units which are scatteredrandomly in the molecule of the polymer, the numerical proportions of A and B being from about 60 to about 99% of A and about 1 to about 40% of B, the viscosity rating being from about 3 to about 3000 cps; in which method, upon contact with the higher pH of the ocular fluid, said liquid formulation is converted to a stiff gel from which the ophthalmic treating agent is slowly released over a prolonged period of time.
摘要翻译：本发明公开了一种持续释放液体水性眼科递送系统和向眼睛的哺乳动物提供缓慢且持续释放眼用治疗剂的方法，其包括向所述哺乳动物的眼睛施用有效量的均匀液体眼用水性药物 pH为约3.0至约6.2的组合物，其以滴剂形式施用，并且其包含眼睛上有效浓度的所述眼科治疗剂和约0.05重量％至约10重量％的聚合物壳聚糖; 所述聚合物基本上由（A）单体β（1-> 4）-D-葡糖胺连接单元和（B）单体β（1-> 4）-D-葡糖胺连接单元组成，其在聚合物，A和B的数值比例为约60至约99％的A和约1至约40％的B，粘度等级为约3至约3000cps; 在该方法中，当与眼液的较高pH接触时，所述液体制剂被转化成刚性凝胶，眼药处理剂在较长时间内缓慢释放。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式